Thus, these results suggest that SLC7A11 inhibition by applying the available clinical drug might be an effective therapy for treating lung cancer patients with both ELF3 overexpression and low levels of PTEN expression or PTEN mutation. Here, SLC7A11 is linked to lung carcinoma.